Fluzoparib Combined With Apatinib in Relapsed Ovarian Carcinoma Maintenance Treatment
Condition(s):Relapsed Ovarian CancerLast Updated:October 13, 2023Not yet recruiting
Hide Studies Not Open or Pending
Condition(s):Relapsed Ovarian CancerLast Updated:October 13, 2023Not yet recruiting
Condition(s):Epithelial Ovarian CancerLast Updated:August 3, 2023Recruiting
Condition(s):Ovarian CancerLast Updated:June 13, 2022Active, not recruiting
Condition(s):Ovarian CancerLast Updated:March 18, 2021Completed
Condition(s):Ovarian CancerLast Updated:August 22, 2022Recruiting
Condition(s):Ovarian CancerLast Updated:August 3, 2023Active, not recruiting
Condition(s):Ovarian Cancer; Chemotherapeutic ToxicityLast Updated:January 16, 2018Unknown status
Condition(s):Epithelial Ovarian Cancer; Peritoneal Cancer; Fallopian Tube CancerLast Updated:June 18, 2023Active, not recruiting
Condition(s):Ovarian Cancer; Peritoneal MetastasisLast Updated:April 10, 2015Completed
Condition(s):Advanced Solid Tumor; Ovarian CancerLast Updated:November 18, 2023Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.